Deal Structure Guides

How life sciences transactions are actually structured.

Thirteen reference guides written for founders, boards, and business development teams who need to understand the mechanics behind a term sheet before they negotiate one. Each guide covers the definition, how the structure works in practice, current benchmarks, and the pitfalls we see most often.

What Is a Contingent Value Right (CVR)?→

A mechanism for bridging valuation gaps in biopharma M&A — and why the structure matters more than the headline number.

How Milestone Structures Work in Biotech Licensing→

Development, regulatory, and commercial milestones — what pays, what doesn't, and how to model achievability.

Royalty Structures in Pharma Licensing Deals→

Tiered royalties, effective rates, and how royalty stacking affects realized economics.

Upfront Payments: What Determines the Number→

Stage, therapeutic area, competitive dynamics, and platform classification drive upfront sizing.

How to Run a Biotech Out-Licensing Process→

From positioning to close — the sequence that determines whether you capture full value.

Anatomy of a Pharma Licensing Term Sheet→

Every clause that matters — and the ones most founders miss.

How Pharma Values Your Asset: rNPV and Beyond→

Risk-adjusted NPV, comparable transactions, and real options — the three frameworks counterparties use.

Running a Sell-Side M&A Process in Biopharma→

Competitive dynamics, buyer psychology, and the timeline that maximizes outcome.

Pharmaceutical M&A Synergy Capture: What the Data Actually Shows→

Acquirers project $300M in synergies, capture $180M, and rarely account for the value they destroy along the way.

Post-Merger Integration in Life Sciences→

The acquisition closes in months. The integration takes years — and what happens during those years determines whether the deal creates value or destroys it.

Biopharma Deal Structuring: Anatomy of How Deals Get Built→

Upfront versus milestone allocations, royalty negotiations, territory carve-outs, and CVR mechanics — what the data shows across 1,600+ transactions.

Biotech Valuation Methods: rNPV, Monte Carlo & Comparables→

Four frameworks, one asset. How the method you choose shapes the number you get — and what 1,600+ verified deals reveal about which approaches hold up.

Biopharma Deal Databases Compared: Choosing the Right Platform in 2026→

Coverage, analytical tools, pricing, and workflow fit — an honest comparison of the platforms BD teams actually rely on.

Bring us your transaction.

We’ll meet you at peer level — anywhere in the world.

Get in Touch Schedule a Call

Issa Kildani

Managing Partner

info@ambrosiaventures.co